Drugs / ST-400
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03432364 | Mar 2018 → Nov 2022 | beta thalassemia | Sangamo Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ST-400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03432364 ↗ |
| Target | BCL11A | “to disrupt a precise and specific sequence of the enhancer of the BCL11A gene” NCT03432364 ↗ |